Neurocrine Biosciences Inc (NBIX) stock
NBIXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 20/3012% below fair value
$167.40−2.00 (-1.18%)
Close on Nov 13, 2026Market cap $17.02BP/E 24.8Yield –
Neurocrine Biosciences gross margin
Gross margin is gross profit as a percentage of revenue.
Neurocrine Biosciences's gross margin for the twelve months ending Sep 30, 2026 was 97.7%. For fiscal 2025 it was 98.2%, against 98.6% the year before. The highest annual figure on record is 100.0% in fiscal 2015.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 98.2% | −0.4 |
| FY2024 | Dec 31, 2024 | 98.6% | +0.7 |
| FY2023 | Dec 31, 2023 | 97.9% | −0.5 |
| FY2022 | Dec 31, 2022 | 98.4% | −0.3 |
| FY2021 | Dec 31, 2021 | 98.7% | −0.3 |
| FY2020 | Dec 31, 2020 | 99.0% | +0.1 |
| FY2018 | Dec 31, 2018 | 98.9% | −0.3 |
| FY2017 | Dec 31, 2017 | 99.2% | −0.8 |
| FY2016 | Dec 31, 2016 | 100.0% | +0.0 |
| FY2015 | Dec 31, 2015 | 100.0% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 97.6% | −0.7 |
| Q2 FY2026 | Jun 30, 2026 | 97.6% | −0.9 |
| Q1 FY2026 | Mar 31, 2026 | 98.3% | −0.1 |
| Q4 FY2025 | Dec 31, 2025 | 97.4% | −1.1 |
| Q3 FY2025 | Sep 30, 2025 | 98.4% | −0.3 |
| Q2 FY2025 | Jun 30, 2025 | 98.5% | +0.1 |
| Q1 FY2025 | Mar 31, 2025 | 98.4% | −0.2 |
| Q4 FY2024 | Dec 31, 2024 | 98.5% | +0.2 |
| Q3 FY2024 | Sep 30, 2024 | 98.7% | +1.0 |
| Q2 FY2024 | Jun 30, 2024 | 98.4% | +1.0 |
| Q1 FY2024 | Mar 31, 2024 | 98.5% | +0.6 |
| Q4 FY2023 | Dec 31, 2023 | 98.4% | +0.2 |
| Q3 FY2023 | Sep 30, 2023 | 97.8% | −0.7 |
| Q2 FY2023 | Jun 30, 2023 | 97.5% | −1.3 |
| Q1 FY2023 | Mar 31, 2023 | 98.0% | −0.5 |
| Q4 FY2022 | Dec 31, 2022 | 98.1% | −0.6 |
| Q3 FY2022 | Sep 30, 2022 | 98.4% | −0.2 |
| Q2 FY2022 | Jun 30, 2022 | 98.7% | −0.2 |
| Q1 FY2022 | Mar 31, 2022 | 98.5% | −0.3 |
| Q4 FY2021 | Dec 31, 2021 | 98.7% | −0.1 |
| Q3 FY2021 | Sep 30, 2021 | 98.6% | −0.4 |
| Q2 FY2021 | Jun 30, 2021 | 98.9% | −0.3 |
| Q1 FY2021 | Mar 31, 2021 | 98.8% | −0.3 |
| Q4 FY2020 | Dec 31, 2020 | 98.8% | −0.2 |
| Q3 FY2020 | Sep 30, 2020 | 99.0% | −0.2 |
| Q2 FY2020 | Jun 30, 2020 | 99.2% | +0.0 |
| Q1 FY2020 | Mar 31, 2020 | 99.1% | +0.3 |
| Q3 FY2019 | Sep 30, 2019 | 99.0% | +0.0 |
| Q2 FY2019 | Jun 30, 2019 | 99.1% | +0.0 |
| Q1 FY2019 | Mar 31, 2019 | 99.2% | +0.5 |
| Q4 FY2018 | Dec 31, 2018 | 98.8% | −0.4 |
| Q3 FY2018 | Sep 30, 2018 | 99.0% | −0.3 |
| Q2 FY2018 | Jun 30, 2018 | 99.1% | +0.1 |
| Q1 FY2018 | Mar 31, 2018 | 98.7% | – |
| Q4 FY2017 | Dec 31, 2017 | 99.2% | – |
| Q3 FY2017 | Sep 30, 2017 | 99.3% | – |
| Q2 FY2017 | Jun 30, 2017 | 99.0% | – |
See a number that looks wrong?